Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

Background: HRAS is a proto-oncogene overexpressed and mutated in head and neck squamous cell carcinomas (HNSCC), bladder, thyroid and salivary gland tumors, among others. Although discovered over 40 years ago, no therapies are yet approved targeting mutant HRAS. Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase, a critical enzyme required for the proper function of HRAS. This Phase 2 study (NCT02383927) was conducted...